NEW YORK (GenomeWeb) – Diagnostics firm Plaxgen has launched its StatRes test for predicting patient response to statins to a limited number of customers.
The Freemont, California-based company has signed an agreement with a regional hospital group in Northern California and will be offering the test at the group's seven facilities, Shanmugavel Madasamy, Plaxgen's founder and CEO, told GenomeWeb this week. He declined to disclose the hospital group's name at this time.
The company is also planning a large-scale clinical validation study of the test, Madasamy said.